Cargando…
PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
Autores principales: | Quartier, P, Brunner, H, Constantin, T, Padeh, S, Calvo, I, Erguven, M, Goffin, L, Hofer, M, Kallinich, T, Oliveira, S, Uziel, Y, Viola, S, Nistala, K, Wouters, C, Lheritier, K, Hruska, J, Abrams, K, Martini, A, Ruperto, N, Lovell, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044930/ http://dx.doi.org/10.1186/1546-0096-11-S2-P169 |
Ejemplares similares
-
Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014) -
Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014) -
Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015) -
PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013) -
Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)